Emerging metallic nanotechnology platforms for cancer sensing and imaging
Nanotechnology blood tests can detect cancer markers like free DNA and tumor cells, with AI integration expanding possibilities for earlier detection.
This comprehensive review from Texas A&M and Dana-Farber surveys emerging metallic nanotechnology biosensing and imaging platforms for cancer detection, including liquid biopsy-compatible approaches for cfDNA/ctDNA, circulating tumor cells, and extracellular vesicles. Integration with AI-driven analytics and theranostic platforms is highlighted as the next frontier.
What the study was
- Study design
- Narrative review
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Nano Today
Why it surfaced
Broad technology survey including liquid biopsy-relevant nanosensors; Nano Today is a well-regarded venue. Preclinical-heavy with mixed species model applicability.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.